GO
Loading...

Genentech Warns of Stroke Risk for Blindness Drug Users

Genentech has sent a letter alerting eye doctors to the risk of stroke from Lucentis, its drug for treating age-related macular degeneration, a spokeswoman said.

The letter was a "proactive effort" to advise doctors that an interim analysis of a large 5,000-patient trial shows that 1.2% of patients given a 0.5-milligram dose of the drug suffered a stroke, compared with 0.3% of patients given a 0.3-mg dose, said spokeswoman Dawn Kalmar.

She said the findings mirror those shown in previous trials of Lucentis, which was approved by the U.S. Food and Drug Administration last year.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video